General
Preferred name
NELFINAVIR
Synonyms
Viracept ()
AG1341 ()
Nelfin ()
AG1343 ()
AG 1343 Mesylate ()
NELFINAVIR MESYLATE ()
Viracept, AG1343 ()
Nelfinavir (AG 1343) Mesylate ()
Nelfinavir (Mesylate) ()
Nelfinaviri mesilas ()
Nelfinavir methanesulfonate ()
AG-1343 ()
Nelfinavir mesilate ()
NSC-747167 ()
Nelfinavir-d3 ()
P&D ID
PD008635
CAS
159989-65-8
159989-64-7
1217629-70-3
Tags
available
drug
Approved by
FDA
First approval
1997
Drug Status
approved
withdrawn
Max Phase
4.0
Drug indication
Kaposi's sarcoma
Carcinoma
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 92
DESCPRITION A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
DESCRIPTION Nelfinavir is an oral antiretroviral drug. It inhibits human immunodeficiency virus (HIV) protease. (GtoPdb)
DESCRIPTION Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent[1][2][3].
PRICE 118
DESCRIPTION Potent VEGFR, PDGFRbeta and KIT inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Nelfinavir is a potent HIV-1 protease inhibitor. It is used in the treatment of HIV infection. (Enamine Bioactive Compounds)
DESCRIPTION Nelfinavir Mesylate (Viracept) is an effective HIV protease inhibitor (Ki: 2 nM). (TargetMol Bioactive Compound Library)
DESCRIPTION An HIV-1 protease inhibitor. It inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. (BOC Sciences Bioactive Compounds)
DESCRIPTION Nelfinavir (AG1341) is an antiretroviral drug used in the treatment of the human immunodeficiency virus (HIV) (Ki=2 nM). Nelfinavir is a broad-spectrum, anticancer agent. (TargetMol Bioactive Compound Library)
Cell lines
2
Organisms
11
Compound Sets
26
Axon Medchem Screening Library
1553
BOC Sciences Bioactive Compounds
nelfinavir-cas-159989-64-7-item-84-455040
Cayman Chemical Bioactives
15144
29416
ChEMBL Approved Drugs
CHEMBL1205
CHEMBL584
ChEMBL Drugs
CHEMBL1205
CHEMBL584
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00220
DrugBank Approved Drugs
DB00220
DrugCentral
1893
DrugCentral Approved Drugs
1893
Enamine Bioactive Compounds
EBC-102086
Guide to Pharmacology
11090
LINCS compound set
10513-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL584
MedChem Express Bioactive Compound Library
HY-15287
NCATS Inxight Approved Drugs
HO3OGH5D7I
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
nelfinavir-mesylate
TargetMol Bioactive Compound Library
T6001
T7779
Tocris Bioactive Compound Library
3766
VGSC-DB
NA0091
NA0092
Withdrawn 2.0
EMA29
External IDs
74
Properties
(calculated by RDKit )
Molecular Weight
567.31
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
2
cLogP
4.75
TPSA
101.9
Fraction CSP3
0.56
Chiral centers
5.0
Largest ring
6.0
QED
0.33
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV Protease
HIV-1
CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7
HIV protease inhibitor
COVID-19,HIV Protease
Primary Target
Other Proteases
MOA
Inhibitor
HIV Protease inhibitor
Indication
human immunodeficiency virus (HIV-1)
ATC
J05AE04
VGSC Target
Nav1.5
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Solubility
In Vitro:<br/>DMSO: ≥ 25 mg/mL (44.03 mM)
Source data